Comparing 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer
ANDROMEDA trial compares alpha and beta PSMA radioligand therapies with SBRT for recurrent oligometastatic prostate cancer, aiming to improve disease control and quality of life.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.